AK-FLUOR 25%
LOE Approachingfluorescein
NDAINTRAVENOUSINJECTABLE
Approved
Aug 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
4/8 — Partial
AK-FLUOR 25% (fluorescein) is 465 to 490 nm and fluoresces, i. Approved for retinal vein occlusion. First approved in 2008.
Drug data last refreshed Yesterday
Mechanism of Action
465 to 490 nm and fluoresces, i.e., emits light at wavelengths of 520 to 530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be…
Indications (1)
Clinical Trials (9)
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Started Nov 2025
10 enrolled
RetinopathyRetinal Vein OcclusionDiabetic Retinopathy+1 more
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Started May 2022
21 enrolled
Osteosarcoma
Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors
Started Aug 2021
2 enrolled
Pediatric Neurosurgical Tumors
Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation
Started Dec 2020
210 enrolled
Intracranial Tumor
Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept
Started Jan 2017
65 enrolled
Retinal Vein Occlusion
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.